Basal Insulin Therapy for Diabetes Management

Basic Characteristics

• The American Diabetes Association recommends that all three insulins, Semglee, Tresiba, and Lantus, are used as part of basal insulin therapy in both type 1 and type 2 diabetes management 1, 4
• Semglee and Lantus are biosimilar products with identical active ingredients, containing insulin glargine 3
• All three insulins are basal insulins designed to provide background insulin coverage throughout the day 1, 2

Pharmacokinetic Differences

• The duration of action of Tresiba is greater than 42 hours, while Lantus and Semglee have approximately 24-hour duration 1, 2
• The onset of action for all three insulins is approximately 2-4 hours after injection 4
• All three insulins have a relatively flat action profile with no pronounced peak 2, 5

Clinical Considerations

• The American College of Physicians recommends that Tresiba offers greater flexibility in dosing time, which can be administered at different times from day to day without compromising glycemic control 1, 6
• The risk of nocturnal hypoglycemia is lower with Tresiba compared to insulin glargine in clinical trials 3
• Both insulin glargine products, Lantus and Semglee, have demonstrated reduced hypoglycemia risk compared to older NPH insulin 3

Efficacy

• All three insulins are effective as basal insulin therapy when properly titrated 1, 3
• Clinical trials have shown that Tresiba achieves similar glycemic control to insulin glargine products, with the main difference being in hypoglycemia risk and dosing flexibility 1

Practical Considerations

• The cost of these products may differ, with biosimilars like Semglee potentially offering cost advantages over brand-name products 1
• All three insulins are available in prefilled pen devices for easier administration 2